

Gillian Gresham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025193/publications.pdf>

Version: 2024-02-01

49
papers

783
citations

516710

16
h-index

526287

27
g-index

53
all docs

53
docs citations

53
times ranked

1555
citing authors

#	ARTICLE	IF	CITATIONS
1	Wearable activity monitors in oncology trials: Current use of an emerging technology. <i>Contemporary Clinical Trials</i> , 2018, 64, 13-21.	1.8	115
2	Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients. <i>Npj Digital Medicine</i> , 2018, 1, 27.	10.9	111
3	Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 95-110.	5.0	83
4	Association Between Palliative Resection of the Primary Tumor and Overall Survival in a Population-Based Cohort of Metastatic Colorectal Cancer Patients. <i>Annals of Surgical Oncology</i> , 2014, 21, 3917-3923.	1.5	42
5	Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with Cancer. <i>Oncologist</i> , 2019, 24, e1460-e1466.	3.7	42
6	Understanding physical activity in cancer patients and survivors: new methodology, new challenges, and new opportunities. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001933.	1.2	37
7	Harms are assessed inconsistently and reported inadequately part 1: systematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 20-27.	5.0	34
8	Fatigability and endurance performance in cancer survivors: Analyses from the Baltimore Longitudinal Study of Aging. <i>Cancer</i> , 2018, 124, 1279-1287.	4.1	33
9	Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019. <i>JAMA Network Open</i> , 2020, 3, e2014682.	5.9	30
10	Exploring the Feasibility and Effects of a Ketogenic Diet in Patients With CNS Malignancies: A Retrospective Case Series. <i>Frontiers in Neuroscience</i> , 2020, 14, 390.	2.8	25
11	Harms are assessed inconsistently and reported inadequately Part 2: nonsystematic adverse events. <i>Journal of Clinical Epidemiology</i> , 2019, 113, 11-19.	5.0	24
12	Evaluating Treatment Tolerability in Cancer Clinical Trials Using the Toxicity Index. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1266-1274.	6.3	24
13	Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas. <i>International Journal of Epidemiology</i> , 2016, 45, 186-205.	1.9	21
14	Impact of Weight Changes After the Diagnosis of Stage III Colon Cancer on Survival Outcomes. <i>Clinical Colorectal Cancer</i> , 2016, 15, 16-23.	2.3	20
15	Population-Based Patterns and Factors Associated With Underuse of Palliative Systemic Therapy in Elderly Patients With Metastatic Colon Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 147-153.	2.3	18
16	Feasibility and efficacy of enteral tube feeding on weight stability, lean body mass, and patient-reported outcomes in pancreatic cancer cachexia. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1959-1968.	7.3	17
17	Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. <i>Systematic Reviews</i> , 2015, 4, 143.	5.3	15
18	KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e309-e315.	2.3	14

#	ARTICLE	IF	CITATIONS
19	Time to Adjuvant Chemotherapy and Survival Outcomes Among Patients With Stage 2 to 3 Rectal Cancer Treated With Preoperative Chemoradiation. <i>Clinical Colorectal Cancer</i> , 2015, 14, 41-45.	2.3	13
20	Methods to identify and prioritize patient-centered outcomes for use in comparative effectiveness research. <i>Pilot and Feasibility Studies</i> , 2018, 4, 95.	1.2	12
21	External validation of the neoadjuvant rectal (NAR) score and Valentini prediction nomogram (VPN): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3532-3532.	1.6	9
22	Priority Rankings of Patient-Reported Outcomes for Pancreatic Ductal Adenocarcinoma: A Comparison of Patient and Physician Perspectives. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1075-1083.	4.9	8
23	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. <i>Medical Oncology</i> , 2018, 35, 110.	2.5	6
24	Evaluation of the effectiveness of an enhanced recovery after surgery program using data from the National Surgical Quality Improvement Program. <i>Canadian Journal of Surgery</i> , 2019, 62, 175-181.	1.2	6
25	A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, e23-e28.	2.3	4
26	A phase I study of nanoliposomal irinotecan and 5-fluorouracil/folinic acid in combination with interleukin-1-alpha antagonist for advanced pancreatic cancer patients with cachexia (OnFX).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4634-4634.	1.6	3
27	Neoadjuvant PET and MRI-based intensity modulated radiotherapy leads to less toxicity and improved pathologic response rates in locally advanced rectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 641-649.	1.4	2
28	ACTR-15. PHASE 1 TRIAL OF A KETOGENIC DIET IN PATIENTS RECEIVING STANDARD-OF-CARE TREATMENT FOR RECENTLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2019, 21, vi15-vi15.	1.2	2
29	A prospective trial of elemental enteral feeding in patients with pancreatic cancer cachexia (PANCAX-1).. <i>Journal of Clinical Oncology</i> , 2020, 38, 726-726.	1.6	2
30	Circulating Sex Hormones and Risk of Colorectal Adenomas and Serrated Lesions in Men. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 293-295.	2.5	2
31	Visualizing adverse events in clinical trials using correspondence analysis with R-package visae. <i>BMC Medical Research Methodology</i> , 2021, 21, 244.	3.1	2
32	Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2020, 4, 514-519.	3.0	1
33	Graphical representations of patient tolerability data: Recommendations from the National Cancer Institute (NCI) Cancer Moonshot Standardization Working Group.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18612-e18612.	1.6	1
34	Association of adjuvant chemotherapy with clinical outcomes in patients treated with neoadjuvant chemoradiation for locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3628-3628.	1.6	1
35	QOLP-04. THE KETOGENIC DIET PLUS STANDARD CARE FOR RECENTLY DIAGNOSED GLIOBLASTOMA: A PHASE 1 SAFETY AND FEASIBILITY TRIAL. <i>Neuro-Oncology</i> , 2021, 23, vi183-vi183.	1.2	1
36	Remote monitoring of sleep activity in patients diagnosed with glioblastoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e14036-e14036.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Treatment and underlying mechanisms of pancreatic cancer cachexia (PANCAX study).. Journal of Clinical Oncology, 2015, 33, TPS491-TPS491.	1.6	0
38	A comparison of prognostic systems in hepatocellular carcinoma treated with sorafenib.. Journal of Clinical Oncology, 2015, 33, e17696-e17696.	1.6	0
39	Predicting protocol completion in randomized clinical trials (RCTs): The occurrence of adverse events in the first treatment cycle.. Journal of Clinical Oncology, 2015, 33, e17700-e17700.	1.6	0
40	Comparing physician and nurse ECOG performance status ratings as predictors of clinical outcomes in cancer patients.. Journal of Clinical Oncology, 2017, 35, 248-248.	1.6	0
41	Rare subtypes of pancreatic cancer: Clinical outcomes and implications for clinical trial enrollment.. Journal of Clinical Oncology, 2019, 37, 445-445.	1.6	0
42	Patient and physician preferences for NIH PROMIS patient-reported outcome (PRO) domains in pancreatic ductal adenocarcinoma (PDA).. Journal of Clinical Oncology, 2019, 37, e15721-e15721.	1.6	0
43	Digitally captured step counts for evaluating performance status in advanced cancer patients: A single cohort, prospective trial (Digi-STEPS).. Journal of Clinical Oncology, 2019, 37, TPS6651-TPS6651.	1.6	0
44	Germline ATM mutations on survival in metastatic pancreatic cancer patients.. Journal of Clinical Oncology, 2020, 38, e16746-e16746.	1.6	0
45	QOLP-20. DIETARY, ACTIVITY, AND QUALITY OF LIFE METRICS IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA IMPLEMENTING A KETOGENIC DIET: RESULTS OF A PHASE 1 CLINICAL TRIAL. Neuro-Oncology, 2021, 23, vi187-vi187.	1.2	0
46	INNV-12. A SINGLE-INSTITUTION RETROSPECTIVE REVIEW OF PATIENTS WITH CNS TUMORS WHO INITIATED A KETOGENIC DIET. Neuro-Oncology, 2020, 22, ii118-ii119.	1.2	0
47	Real-world clinical outcomes and molecular features of lung-specific and liver-specific metastases in pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2022, 40, 532-532.	1.6	0
48	Impact of site-specific metastases on survival outcomes in pancreatic adenocarcinoma (PDAC) patients: A national analysis.. Journal of Clinical Oncology, 2022, 40, e16270-e16270.	1.6	0
49	Association between remotely-monitored activity, patient-reported outcomes, and physical function in patients with advanced pancreatic cancer.. Journal of Clinical Oncology, 2022, 40, 1572-1572.	1.6	0